Columbia and HCA divests as HealthSouth buys ASC
This article was originally published in Clinica
Columbia/HCA has cancelled hospital building and plans to sell most of the recently-acquired Value Health business. At the same time, HealthSouth, which has shown interest in acquiring some or all of the beleaguered healthcare group, will pay $180 million in cash and debt assumption for a chain of 29 surgery centres. Columbia recently paid $1.1 billion for Value Health and now intends to sell its pharmacy benefits management company which represents around 80% of Value Health's $1.8 billion turnover. Columbia will also shed the managed care company specialising in behavioural therapy and the information technology-based disease management division.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.